DDInter1139 DDInter1094
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Mefenamic acid {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetohexamide
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Oxybenzone
Oxybenzone {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Nepafenac
Nepafenac {u} (Compound) resembles {v} (Compound) Modafinil
Modafinil {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Diclofenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triamcinolone
Triamcinolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Nepafenac
Nepafenac {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} may lead to a major life threatening interaction when taken with {v} Betrixaban
Betrixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pantoprazole
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetohexamide
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Mefenamic acid (Compound) resembles Ketoprofen (Compound) and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mefenamic acid (Compound) resembles Ketoprofen (Compound) and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mefenamic acid (Compound) resembles Oxybenzone (Compound) and Oxybenzone (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mefenamic acid (Compound) resembles Nepafenac (Compound) and Nepafenac (Compound) resembles Modafinil (Compound) and Modafinil may lead to a major life threatening interaction when taken with Lorlatinib
Mefenamic acid (Compound) resembles Diclofenac (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mefenamic acid (Compound) resembles Nepafenac (Compound) and Nepafenac (Compound) resembles Ketoprofen (Compound) and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mefenamic acid (Compound) resembles Ketoprofen (Compound) and Ketoprofen may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mefenamic acid (Compound) resembles Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Pantoprazole and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mefenamic acid (Compound) resembles Ketoprofen (Compound) and Ketoprofen (Compound) resembles Warfarin (Compound) and Ketoprofen may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mefenamic acid (Compound) resembles Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib